trial

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

NCTId NCT01050478
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 56 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
56 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2010-03
Primary completion
2011-12
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
PaliperidoneBenzodiazepine

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
56
Phase
PHASE4
Primary Completion Date
2011-12
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
Benzodiazepine
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Acute Disease
indication
Psychomotor Agitation
indication
Aggression
indication